Literature DB >> 8133537

Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial.

F L Meyskens1, E Surwit, T E Moon, J M Childers, J R Davis, R T Dorr, C S Johnson, D S Alberts.   

Abstract

BACKGROUND: Retinoids enhance differentiation of most epithelial tissues. Epidemiologic studies have shown an inverse relationship between dietary intake or serum levels of vitamin A and the development of cervical dysplasia and/or cervical cancer. Pilot and phase I investigations demonstrated the feasibility of the local delivery of all-trans-retinoic acid (RA) to the cervix using a collagen sponge insert and cervical cap. A phase II trial produced a clinical complete response rate of 50%.
PURPOSE: This randomized phase III trial was designed to determine whether topically applied RA reversed moderate cervical intraepithelial neoplasia (CIN) II or severe CIN.
METHODS: Analyses were based on 301 women with CIN (moderate dysplasia, 151 women; severe dysplasia, 150 women), evaluated by serial colposcopy, Papanicolaou cytology, and cervical biopsy. Cervical caps with sponges containing either 1.0 mL of 0.372% beta-trans-RA or a placebo were inserted daily for 4 days when women entered the trial, and for 2 days at months 3 and 6. Patients receiving treatment and those receiving placebo were similar with respect to age, ethnicity, birth-control methods, histologic features of the endocervical biopsy specimen and koilocytotic atypia, and percentage of involvement of the cervix at study. Treatment effects were compared using Fisher's exact test and logistic regression methods. Side effects were recorded, and differences were compared using Fisher's exact test.
RESULTS: RA increased the complete histologic regression rate of CIN II from 27% in the placebo group to 43% in the retinoic acid treatment group (P = .041). No treatment difference between the two arms was evident in the severe dysplasia group. More vaginal and vulvar side effects were seen in the patients receiving RA, but these effects were mild and reversible.
CONCLUSIONS: A short course of locally applied RA can reverse CIN II, but not more advanced dysplasia, with acceptable local side effects. IMPLICATIONS: A derivative of vitamin A can reverse or suppress an epithelial preneoplasia, lending further support to the notion that chemoprevention of human cancer is feasible.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8133537     DOI: 10.1093/jnci/86.7.539

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  40 in total

Review 1.  DFMO: targeted risk reduction therapy for colorectal neoplasia.

Authors:  Christina M Laukaitis; Eugene W Gerner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

Review 2.  Open questions in oesophageal adenocarcinogenesis.

Authors:  Carlo C Maley
Journal:  Gut       Date:  2007-07       Impact factor: 23.059

3.  Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic.

Authors:  Frank L Meyskens; Gregory A Curt; Dean E Brenner; Gary Gordon; Ronald B Herberman; Olivera Finn; Gary J Kelloff; Samir N Khleif; Caroline C Sigman; Eva Szabo
Journal:  Cancer Prev Res (Phila)       Date:  2011-03

4.  Decreased Expression of Retinoid X Receptors During Human and Azoxymethane-induced Colorectal Carcinogenesis in the Rat.

Authors:  Xingpei Hao; Hang Xiao; Jihyueng Ju; Stephen M Hewitt; Herbert C Morse
Journal:  Anticancer Res       Date:  2016-06       Impact factor: 2.480

5.  Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype.

Authors:  Cornelia L Trimble; Steven Piantadosi; Patti Gravitt; Brigitte Ronnett; Ellen Pizer; Andrea Elko; Barbara Wilgus; William Yutzy; Richard Daniel; Keerti Shah; Shiwen Peng; Chienfu Hung; Richard Roden; Tzyy Choou Wu; Drew Pardoll
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

6.  A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Janet S Rader; Michael W Sill; Jan H Beumer; Heather A Lankes; Doris Mangiaracina Benbrook; Francisco Garcia; Connie Trimble; J Tate Thigpen; Richard Lieberman; Rosemary E Zuna; Charles A Leath; Nick M Spirtos; John Byron; Premal H Thaker; Shashikant Lele; David Alberts
Journal:  Gynecol Oncol       Date:  2017-03-10       Impact factor: 5.482

7.  Suppression of growth by all-trans retinoic acid requires prolonged induction of interferon regulatory factor 1 in cervical squamous carcinoma (SiHa) cells.

Authors:  Istvan Arany; William E Whitehead; Kenneth J Grattendick; Istvan A Ember; Stephen K Tyring
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

Review 8.  Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis.

Authors:  V A Papadimitrakopoulou; D M Shin; W K Hong
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

9.  Cervical and Vulvar Intraepithelial Neoplasia after Treatment with Oral Isotretinoin for Severe Acne Vulgaris.

Authors:  M N Al Hallak; N Zouain
Journal:  Case Rep Dermatol       Date:  2009-09-30

Review 10.  Nutrition and cervical neoplasia.

Authors:  N Potischman; L A Brinton
Journal:  Cancer Causes Control       Date:  1996-01       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.